期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Inhibition effects of parathyroid hormone on human medullary thyroid carcinoma cells 被引量:1
1
作者 Yaqiong Ni Qinjiang Liu +1 位作者 Shihong Ma Ruihui Chen 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第5期224-228,共5页
Objective: The purpose of the study was to investigate the effects of parathyroid hormone and parathyroid hormone receptor monoclonal antibody on in vitro growth and proliferation of human medullary thyroid carcinoma... Objective: The purpose of the study was to investigate the effects of parathyroid hormone and parathyroid hormone receptor monoclonal antibody on in vitro growth and proliferation of human medullary thyroid carcinoma cell lines. Methods: The medullary thyroid carcinoma cell line was cultured in vitro, with parathyroid hormone and parathyroid hormone receptor monoclonal antibody treatment intervention, the growth of the cells was observed under an inverted contrast micro scope, the MTT assay was used to detect the cell growth inhibition rate. Results: Under the inverted contrast microscope, the cells changed significantly, the parathyroid hormone and parathyroid hormone receptor monoclonal antibodies can effectively inhibit the proliferation of medullary thyroid cancer cells in a time and dose dependent. When parathyroid hormone concentra tion reached a concentration of 2.0 IJmol/L, the parathyroid hormone receptor monoclonal antibody reached a concentration of 1.0 μmol/L, the cell growth was most significantly inhibited (P 〈 0.05). Conclusion: Parathyroid hormone and parathyroid hormone receptor monoclonal antibody were able to inhibit the proliferation of medullary thyroid carcinoma cells and signifi cantly reduce the proliferation index. 展开更多
关键词 parathyroid hormone (PTH) medullary thyroid carcinoma (MTC) cell line parathyroid hormone receptor mono-clonal antibody
下载PDF
奥曲肽敏感试验预测长效生长抑素受体配体治疗垂体GH腺瘤的疗效 被引量:5
2
作者 李冉 段炼 +7 位作者 潘慧 杨盛旻 王林杰 阳洪波 龚凤英 柯晓安 陈美平 朱惠娟 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2022年第4期288-293,共6页
目的探究奥曲肽敏感试验预测生长抑素受体配体(somatostatin receptor ligands,SRLs)治疗活动性肢端肥大症的临床应用价值。方法回顾性分析2011年至2020年间76例未接受过放射治疗的活动性肢端肥大症患者的临床资料,所有患者均在晨起空... 目的探究奥曲肽敏感试验预测生长抑素受体配体(somatostatin receptor ligands,SRLs)治疗活动性肢端肥大症的临床应用价值。方法回顾性分析2011年至2020年间76例未接受过放射治疗的活动性肢端肥大症患者的临床资料,所有患者均在晨起空腹状态下皮下注射短效奥曲肽100μg,分别在0、2、4、6和8 h采血测定血清生长激素(GH)水平,所有患者均接受SRLs治疗至少3个月。SRLs治疗有效的标准为:治疗后血清随机GH<1μg/L或GH较基线值下降>80%定义为GH有效;治疗后血清胰岛素样生长因子Ⅰ(IGF-Ⅰ)<1.3倍参考范围上限(upper limit of normal,ULN)或IGF-Ⅰ较基线值下降>50%定义为IGF-Ⅰ有效;同时满足GH和IGF-Ⅰ有效的标准定义为GH和IGF-Ⅰ均有效。结果奥曲肽敏感试验中基线GH为15.00(6.38,34.20)μg/L,血清GH达到谷值的时间为(3.65±1.65)h,GH谷值为1.47(0.50,4.19)μg/L,GH抑制率为89.12%(72.71%,95.09%)。奥曲肽敏感试验中GH抑制率为89.32%时,曲线下面积(AUC)为0.74,预测GH有效的敏感度为81.80%,特异度为66.00%;GH抑制率为93.14%时,AUC为0.64,预测IGF-Ⅰ有效的敏感度和特异度分别为50.00%、75.60%;GH抑制率为90.71%时,AUC为0.78,预测GH和IGF-Ⅰ同时有效的敏感度为83.30%,特异度为70.00%。GH/IGF-Ⅰ有效组较GH/IGF-Ⅰ无效组奥曲肽敏感试验中GH谷值更低、GH抑制率更高、IGF-Ⅰ下降率更高、治疗后IGF-Ⅰ/ULN比值更低(P<0.05)。结论奥曲肽敏感试验中GH抑制率可以用来预测SRLs治疗垂体GH腺瘤的疗效,诊断界值为90.71%时敏感度和特异度最高。 展开更多
关键词 奥曲肽敏感试验 长效生长抑素受体配体 肢端肥大症 生长激素抑制率
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部